FDA Designation
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Array BioPharma
PR-M08-18-NI-070Aug 16, 2018
Clinical Trials
Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib)
Genentech
PR-M05-18-NI-048May 14, 2018